Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. November 2024 07:00 ET | Quelle: Medicenna Therapeutics Corp.

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with...
08. November 2024 19:00 ET | Quelle: Girard Sharp LLP

INVESTIGATION NOTICE: Girard Sharp Law Firm Encourages Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) Investors with losses to Contact the Firm

SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Girard Sharp, LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of Evolv...
08. November 2024 16:00 ET | Quelle: Bronstein, Gewirtz & Grossman, LLC

OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been...
08. November 2024 09:00 ET | Quelle: Kineta, Inc.

Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed...
08. November 2024 07:00 ET | Quelle: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
08. November 2024 07:00 ET | Quelle: Girard Sharp LLP

INVESTIGATION NOTICE: Girard Sharp Law Firm Encourages PACS Group, Inc. (NYSE: PACS) Investors with losses to Contact the Firm

SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Girard Sharp, LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of PACS...
08. November 2024 06:17 ET | Quelle: Research and Markets

Julius Baer Competitor Profile Report 2024: Insights into the Company's Strategy and Financial Performance, Including Key Data on Assets Under Management

Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Competitor Profile: Julius Baer 2024" company profile has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive...
07. November 2024 16:23 ET | Quelle: Hagens Berman Sobol Shapiro LLP

iLearningEngines (AILE) Faces Investor Class Action - Hagens Berman

SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- A scathing report from a renowned activist short seller has cast doubt on the financial health and business model of iLearningEngines (NASDAQ: AILE)...
07. November 2024 14:52 ET | Quelle: Texas A&M University-Commerce

Texas A&M University System Board of Regents Approves Name Change for Texas A&M University-Commerce

Commerce, TX, Nov. 07, 2024 (GLOBE NEWSWIRE) -- During its quarterly meeting on November 7, 2024, The Texas A&M University System Board of Regents voted to change the name of Texas A&M...
07. November 2024 11:40 ET | Quelle: Banijay Group N.V.

Banijay Group: 9M 2024 results

Press Release Paris, 7 November 2024 First nine-month 2024 Results +15% ADJUSTED EBITDA GROWTH IN 9M 2024 GUIDANCE CONFIRMED FOR...

Vorherige Seite

Nächste Seite